Remdesivir (new indication: COVID-19, patients not requiring supplemental oxygen, with increased risk of progressing to severe COVID-19)


  • Active Substance: Remdesivir
  • Name: Veklury®
  • Therapeutic area: Coronavirus disease 2019 (COVID-19)
  • Pharmaceutical company: Gilead Sciences GmbH

Time table:

  • Start: 15.01.2022
  • Final decision by G-BA: 07.07.2022

Final decision:

  • Hint for a minor additional benefit